Pfizer Reports Completion of Metsera Acquisition
Summary
Pfizer Inc. completed its acquisition of Metsera, Inc. on November 13, 2025. The deal, representing an enterprise value of approximately $7.0 billion, involved Metsera shareholders receiving $65.60 in cash per share at closing. Additionally, shareholders received contingent value rights (CVRs) for potential payments up to $20.65 per share, linked to the achievement of three specific clinical and regulatory milestones for Metsera's GLP-1 receptor antagonist programs.
Why It Matters
This acquisition significantly expands Pfizer's pipeline in the GLP-1 receptor antagonist space with Metsera's programs, including MET-097i and MET-233i. The $7.0 billion enterprise value and potential additional CVR payments up to $20.65 per share highlight a substantial investment in a key therapeutic area, with future payments contingent on critical development and regulatory milestones.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how PFE traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View PFE Charts on TradingViewAffiliate link
Filing Details
Reported Items
Additional Information
- CIK Number
- 0000078003
- Filing Date
- Thursday, November 13, 2025
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- positive